biosimilar

drug prices biologics drug costs IRA money cash payment co-pay
Pharma

Inside the turning tides of the US biosimilar market

The biosimilar landscape features shifting policies, key patent cliffs and the threat of the "biosimilar void."
Zoey Becker Jan 8, 2026 9:00am
Sandoz

Sandoz's biosimilar to Biogen's Tysabri hits the US after delay

Nov 17, 2025 11:12am
red light stop light street traffic signal

Alvotech plant issues trigger another FDA biosimilar rejection

Nov 4, 2025 7:40am
partnership collaboration legal document

Regeneron, Celltrion shake hands on Eylea biosimilar settlement

Oct 22, 2025 8:15am
Novartis Sandoz

Sandoz pumps $440M into another Slovenia biosimilar plant

Jul 2, 2025 9:10am
layoffs job cuts fired exit restructuring layoff reduction

Coherus loses commercial chief amid exit from biosimilar space

Apr 23, 2025 11:19am